A phase II clinical trial evaluating the use of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors, including olfactory neuroblastoma, was recently initiated, and the results will be relevant to cases like the one reported here [18]. This evidence concerns the gene IDH2 and skull base neoplasm.